PL2165704T3 - Zastosowanie alweryny w leczeniu dolegliwości skórnych - Google Patents

Zastosowanie alweryny w leczeniu dolegliwości skórnych

Info

Publication number
PL2165704T3
PL2165704T3 PL09171044T PL09171044T PL2165704T3 PL 2165704 T3 PL2165704 T3 PL 2165704T3 PL 09171044 T PL09171044 T PL 09171044T PL 09171044 T PL09171044 T PL 09171044T PL 2165704 T3 PL2165704 T3 PL 2165704T3
Authority
PL
Poland
Prior art keywords
alverine
treatment
antibacterial
salts
cutaneous affections
Prior art date
Application number
PL09171044T
Other languages
English (en)
Inventor
François Fauran
Original Assignee
Fauran Francois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fauran Francois filed Critical Fauran Francois
Publication of PL2165704T3 publication Critical patent/PL2165704T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
PL09171044T 2008-09-23 2009-09-23 Zastosowanie alweryny w leczeniu dolegliwości skórnych PL2165704T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0856382A FR2936149B1 (fr) 2008-09-23 2008-09-23 Utilisation de l'alverine dans le traitement des affections cutanees
EP09171044A EP2165704B1 (fr) 2008-09-23 2009-09-23 Utilisation de l'alvérine dans le traitement des affections cutanées

Publications (1)

Publication Number Publication Date
PL2165704T3 true PL2165704T3 (pl) 2012-10-31

Family

ID=40513974

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09171044T PL2165704T3 (pl) 2008-09-23 2009-09-23 Zastosowanie alweryny w leczeniu dolegliwości skórnych

Country Status (7)

Country Link
EP (1) EP2165704B1 (pl)
AT (1) ATE553760T1 (pl)
DK (1) DK2165704T3 (pl)
ES (1) ES2386558T3 (pl)
FR (1) FR2936149B1 (pl)
PL (1) PL2165704T3 (pl)
PT (1) PT2165704E (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083651A1 (es) † 2010-10-21 2013-03-13 Galderma Sa Composiciones de brimonidina en gel y metodos de uso
CN102626415B (zh) * 2012-03-21 2014-08-06 山东省千佛山医院 四环素类药物联合应用氟康唑在制备抗真菌产品中的应用及其产品
WO2014009764A1 (en) * 2012-07-13 2014-01-16 L'oreal S.A. Method of in vitro diagnosing a pellicular state in a subject and related applications
KR102057173B1 (ko) 2018-04-05 2019-12-18 삼척시 알베린 화합물을 유효성분으로 포함하는 항산화 조성물
KR102261340B1 (ko) * 2018-12-28 2021-06-07 삼척시 민물김 추출물을 유효성분으로 포함하는 염증성 피부 질환 예방 또는 치료용 조성물
WO2022018297A1 (en) * 2020-07-24 2022-01-27 Association Francaise Contre Les Myopathies Use of alverine or its derivatives for the treatment of mitochondrial diseases or dysfunction associated with mitochondrial complex i deficiencies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2798590B1 (fr) 1999-09-21 2001-11-30 Oreal Utilisation de l'alverine pour diminuer les rides
FR2823109B1 (fr) 2001-04-09 2003-05-23 Oreal Utilisation de l'alverine ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2823114B1 (fr) * 2001-04-09 2003-05-23 Oreal Utilisation de l'alverine ou de l'un de ses sels
FR2826267B1 (fr) * 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un agent myorelaxant
EP1641445A1 (fr) 2003-06-13 2006-04-05 Cerep Utilisation de l'alverine, seul ou en combinaison avec un antidepresseur tricyclique ou un antidepresseur inhibiteur specifique de la recapture de la serotonine pour le traitement de la depression
FR2900337A1 (fr) 2006-04-28 2007-11-02 Cerep Sa Utilisation de l'alverine pour le traitement des dysfonctions sexuelles
WO2008009860A2 (fr) * 2006-07-21 2008-01-24 L'oreal Utilisation de composés antagonistes des canaux calcium pour dépigmenter la peau

Also Published As

Publication number Publication date
EP2165704A1 (fr) 2010-03-24
EP2165704B1 (fr) 2012-04-18
ATE553760T1 (de) 2012-05-15
FR2936149A1 (fr) 2010-03-26
PT2165704E (pt) 2012-07-05
DK2165704T3 (da) 2012-08-06
FR2936149B1 (fr) 2013-01-04
ES2386558T3 (es) 2012-08-22

Similar Documents

Publication Publication Date Title
PL2165704T3 (pl) Zastosowanie alweryny w leczeniu dolegliwości skórnych
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2010056302A3 (en) Iontophoretic therapeutic agent delivery system
MY160894A (en) Oligosaccharide composition for treating skin diseases
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
MY147864A (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
MY160004A (en) Heterocyclically substituted aryl compounds as hif inhibitors
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
WO2011021892A3 (ko) 헥사미딘류 및 레티노이드류를 함유하는 피부 개선 조성물
EP2161023A3 (en) Anti-angiogenic agents and methods of use.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
WO2011056871A3 (en) Rhamnolipid mechanism
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
IN2012DN00953A (pl)
WO2008046407A3 (de) Verwendung von deuteriumdioxid zur behandlung von hyperproliferativen erkrankungen der haut
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
MX344183B (es) Proteina antimicrobiana.
CL2008001282A1 (es) Composicion farmaceutica con actividad antimicrobiana que comprende un aminoacidos n halogenado y un agente antiinflamatorio; uso para prevenir o tratar una infeccion de tejidos, donde dicho tejido es ocular, nasal, seno nasal o dermico o una infeccion respiratoria.
MX2007001206A (es) Metodos para tratar la piel para mejorar el tratamiento terapeutico de la misma.
WO2007120665A3 (en) Formulation and method for a skin treatment for animals
NZ594450A (en) Antimicrobial composition
WO2011015758A3 (fr) Utilisation de n-hexadecanoyl isoleucine comme agent "volumateur" et/ou comme agent "repulpant" de la peau humaine